Atopic eczema eczema
Conditions
Interventions
Subjects allocated to the intervention group receive a potent CS class III once
daily.
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in the cohort study,a subject must meet all of the following criteria: - Age >12 weeks
Exclusion criteria
Exclusion criteria: A potential patient who meets any of the following criteria will be excluded from participation in the cohort study: - As determined by the GP (e.g. family problems) - Currently under treatment of a dermatologist (this is not an exclusion criterion for open recruitment of the cohort) - Language barrier - No access to internet (necessary to fill in weekly online questionnaire) - Contra-indications for the study medication: * previously side effects with any of the medications * hypersensitivity to corticosteroids, A potential patient who meets any of the following criteria will be excluded from participation in the trial: - Use of CS in 2 weeks before inclusion in trial - >50% of body affected - Other skin disorders hampering proper assessment of eczema - AD on eyelid(s). - Pregnancy and or breastfeeding - Contra-indications for the study medication: * untreated skin infections caused by a bacterium, virus, fungal, or parasite * incurable wounds, ulcerative skin disorders * ichthyoses, acne vulgaris, rosacea, juvenile plantar dermatosis, skin atrophy, skin lesions * diaper rash * perianal and genital itching
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in disease severity after 24 weeks follow-up in the trial, measured with the Patient-Oriented Eczema Measure (POEM). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes concerning trial - Changes in subjective disease severity after 1 week and 4 weeks of FU (POEM) - Changes in objective disease severity after 1 week, 4 weeks and 24 weeks of FU (EASI) - Quality of life - Compliance - Local side-effects - Systemic side-effects - Time to recovery - Frequency of flare-ups - Medication use - Healthcare use Secondary outcomes concerning cohort: - Severity of disease - Quality of life - Frequency of flare-ups - Medication use - Healthcare use | — |
Countries
Netherlands
Outcome results
None listed